The present disclosure relates to recombinant EGFL7, EGFL7 antibodies, and uses thereof.

The present disclosure provides compositions and methods for culturing hematopoietic stem and progenitor cells, while maintaining or increasing the subpopulation of hematopoietic stem cells (HSCs). The methods and compositions describe us a 3D zwitterionic hydrogel to provide a biocompatible culture microenvironment for culturing encapsulated hematopoietic stem and progenitor cells.

The invention relates to induced pluripotent stem cells that are generated from cells, for example Adult Stem Cells, that are conditionally-immortalisable. In particular, the invention relates to induced pluripotent stem cells generated from stem cell lines comprising a controllable transgene for conditional immortalisation, and the progeny of those induced pluripotent stem cells such as cells of the haematopoietic lineage. Induced pluripotent stem cells, haematopoietic progeny cells derived from those pluripotent cells, compositions comprising those cells, methods of making all of those cells, and uses of all of those cells are also described.

Provided herein are CRIS-PR/Cas9 complexes and methods of using same.

The purpose of the invention is to provide a novel hematopoiesis-promoting agent and a medicament comprising the hematopoiesis-promoting agent as an active ingredient for preventing or treating anemia, in particular refractory anemia. The present invention provides a hematopoiesis-promoting agent comprising an S-adenosylmethionine synthase inhibitor.

A pharmaceutical includes helper T cells induced from pluripotent stem cells. The helper T cells include CD4-positive CD40L-highly expressing T cells, dendritic cells, antigen, and cytotoxic T cells CD8-positive T cells. The pharmaceutical can be administered in a method for treating cancer to a patient having cancer cells expressing an antigen specifically recognized by CD4-positive T cells.

In some aspects and embodiments, the invention provides methods for making hematopoietic stem cells, including for HSCT. The method comprises providing a cell population comprising hemogenic endothelial (HE) or endothelial cells, and increasing activity or expression of DNA (cytosine-5-)-methyltransferase 3 beta (Dnmt3b) and/or GTPase IMAP Family Member 6 (Gimap6) in the HE and/or endothelial cells under conditions sufficient for stimulating formation of HSCs.

Methods and compositions are described herein that involve expansion of hematopoietic stem cells and/or hematopoietic progenitor cells.

Certain exemplary embodiments are directed to a biologically active composition of matter (and uses thereof) configured for targeted delivery of biotin to mitochondria, the composition comprising a first D-biotin conjugated to a water-soluble, cell-permeable, peptide sequence, wherein the peptide sequence is selected from a polypeptide group with an alternating aromatic-cationic motif.

A composition and a method for generating clinically safe NK cells derived from non-fully differentiated stem cells are provided. The non-fully differentiated stem cells are co-cultured with endogenous NK cells isolated from adipocyte-containing tissue to generate a high percentage of clinically safe NK cells, where anti-tumor activity of the clinically safe NK cells in vitro is similar to that of endogenous NK cells. Optimized Production of the clinically safe autologous NK cells from stem cells provides platform for treating cancer patients by applying an effective adoptive immunotherapy ranging from the early to terminal stages.